UBS Initiates Coverage On Viking Therapeutics with Buy Rating, Announces Price Target of $94

UBS analyst Joon Lee has initiated coverage on Viking Therapeutics (NASDAQ: VKTX) with a Buy rating. The firm has set a price target of $94 for the stock.